{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:34:03Z","timestamp":1790192043392,"version":"4.1.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11596-024-2859-1","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T04:44:50Z","timestamp":1712033090000},"page":"261-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["DNA Damage-driven Inflammatory Cytokines: Reprogramming of Tumor Immune Microenvironment and Application of Oncotherapy"],"prefix":"10.1007","volume":"44","author":[{"given":"Meng-jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"issue":"7525","key":"2859_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nature13862","volume":"515","author":"L Bonapace","year":"2014","unstructured":"Bonapace L, Coissieux MM, Wyckoff J, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature, 2014,515(7525):130\u2013133","journal-title":"Nature"},{"key":"2859_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ecoenv.2017.06.022","volume":"144","author":"PK M K","year":"2017","unstructured":"M K PK, Shyama SK, D\u2019Costa A, et al. Evaluation of DNA damage induced by gamma radiation in gill and muscle tissues of Cyprinus carpio and their relative sensitivity. Ecotoxicol Environ Saf, 2017,144:166\u2013170","journal-title":"Ecotoxicol Environ Saf"},{"issue":"2","key":"2859_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","volume":"12","author":"D Fu","year":"2012","unstructured":"Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer, 2012,12(2):104\u2013120","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2859_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/v6052155","volume":"6","author":"E Xiaofei","year":"2014","unstructured":"Xiaofei E, Kowalik TF. The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses, 2014,6(5):2155\u20132185","journal-title":"Viruses"},{"issue":"1","key":"2859_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrg3345","volume":"14","author":"M Papamichos-Chronakis","year":"2013","unstructured":"Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet, 2013,14(1):62\u201375","journal-title":"Nat Rev Genet"},{"issue":"4","key":"2859_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms22041726","volume":"22","author":"C Romei","year":"2021","unstructured":"Romei C, Elisei R. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Int J Mol Sci, 2021,22(4):1726","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2859_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00018-003-3223-4","volume":"61","author":"TM Marti","year":"2004","unstructured":"Marti TM, Fleck O. DNA repair nucleases. Cell Mol Life Sci, 2004,61(3):336\u2013354","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2859_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 2019,51(1):27\u201341","journal-title":"Immunity"},{"issue":"2","key":"2859_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jare.2015.06.001","volume":"7","author":"ML Salem","year":"2016","unstructured":"Salem ML, Attia ZI, Galal SM. Acute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model. J Adv Res, 2016,7(2):243\u2013253","journal-title":"J Adv Res"},{"key":"2859_CR10","doi-asserted-by":"publisher","first-page":"109387","DOI":"10.1016\/j.intimp.2022.109387","volume":"113","author":"Z Al-Kadhimi","year":"2022","unstructured":"Al-Kadhimi Z, Callahan M, Fehniger T, et al. Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy. Int Immunopharmacol, 2022,113(Pt A):109387","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2859_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2005.07.006","volume":"16","author":"A Ben-Baruch","year":"2006","unstructured":"Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol, 2006,16(1):38\u201352","journal-title":"Semin Cancer Biol"},{"issue":"1\u20132","key":"2859_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mrrev.2008.03.002","volume":"659","author":"JK Kundu","year":"2008","unstructured":"Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res, 2008,659(1\u20132):15\u201330","journal-title":"Mutat Res"},{"key":"2859_CR13","first-page":"15","volume":"2008","author":"W Cai","year":"2008","unstructured":"Cai W, Kerner ZJ, Hong H, et al. Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights, 2008,2008:15\u201321","journal-title":"Biochem Insights"},{"issue":"7","key":"2859_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev, 2012,38(7):904\u2013910","journal-title":"Cancer Treat Rev"},{"key":"2859_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pharmthera.2014.11.001","volume":"147","author":"C Neuzillet","year":"2015","unstructured":"Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGF\u03b2 pathway for cancer therapy. Pharmacol Ther, 2015,147:22\u201331","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2859_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13046-019-1072-8","volume":"38","author":"J Wei","year":"2019","unstructured":"Wei J, Ma L, Lai YH, et al. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. J Exp Clin Cancer Res, 2019,38(1):63","journal-title":"J Exp Clin Cancer Res"},{"key":"2859_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol, 2015,10:425\u2013448","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"2859_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability\u2014an evolving hallmark of cancer. Nat Rev Mol Cell Biol, 2010,11(3):220\u2013228","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"2859_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond), 2022,42(8):689\u2013715","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"2859_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cell.2017.07.043","volume":"170","author":"S Hamperl","year":"2017","unstructured":"Hamperl S, Bocek MJ, Saldivar JC, et al. Transcription-Replication Conflict Orientation Modulates R-Loop Levels and Activates Distinct DNA Damage Responses. Cell, 2017,170(4):774\u2013786","journal-title":"Cell"},{"key":"2859_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-biochem-061516-044813","volume":"86","author":"K Kato","year":"2017","unstructured":"Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA. Annu Rev Biochem, 2017,86:541\u2013566","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"2859_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2013.04.046","volume":"153","author":"P Gao","year":"2013","unstructured":"Gao P, Ascano M, Wu Y, et al. Cyclic [G(2\u2019,5\u2019)pA(3\u2019,5\u2019) p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell, 2013,153(5):1094\u20131107","journal-title":"Cell"},{"issue":"7213","key":"2859_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature, 2008,455(7213):674\u2013678","journal-title":"Nature"},{"issue":"7748","key":"2859_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","volume":"567","author":"C Zhang","year":"2019","unstructured":"Zhang C, Shang G, Gui X, et al. Structural basis of STING binding with and phosphorylation by TBK1. Nature, 2019,567(7748):394\u2013398","journal-title":"Nature"},{"issue":"214","key":"2859_CR25","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2002521","volume":"5","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal, 2012,5(214):ra20","journal-title":"Sci Signal"},{"issue":"1","key":"2859_CR26","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1038\/s41467-022-31132-7","volume":"13","author":"C Yang","year":"2022","unstructured":"Yang C, Bachu M, Du Y, et al. CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes. Nat Commun, 2022,13(1):3426","journal-title":"Nat Commun"},{"key":"2859_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.fsi.2018.06.045","volume":"80","author":"N Yu","year":"2018","unstructured":"Yu N, Xu X, Qi G, et al. Ctenopharyngodon idella TBK1 activates innate immune response via IRF7. Fish Shellfish Immunol, 2018,80:521\u2013527","journal-title":"Fish Shellfish Immunol"},{"issue":"10","key":"2859_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.celrep.2023.113126","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Song D, Chen Y, et al. NSD2 methylates AROS to promote SIRT1 activation and regulates fatty acid metabolism-mediated cancer radiotherapy. Cell Rep, 2023,42(10):113\u2013126","journal-title":"Cell Rep"},{"issue":"11","key":"2859_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/iub.1566","volume":"68","author":"J Tao","year":"2016","unstructured":"Tao J, Zhou X, Jiang Z. cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB life, 2016,68(11):858\u2013870","journal-title":"IUBMB life"},{"issue":"1","key":"2859_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41419-020-03341-9","volume":"12","author":"Q Guo","year":"2021","unstructured":"Guo Q, Chen X, Chen J, et al. STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-\u03baB signaling pathway. Cell Death Dis, 2021,12(1):13","journal-title":"Cell Death Dis"},{"issue":"6","key":"2859_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","volume":"25","author":"G Bonizzi","year":"2004","unstructured":"Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004,25(6):280\u2013288","journal-title":"Trends Immunol"},{"issue":"1","key":"2859_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-\u03baB signaling pathway. Cell Res, 2011,21(1):71\u201385","journal-title":"Cell Res"},{"issue":"51","key":"2859_CR33","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 2006,25(51):6680\u20136684","journal-title":"Oncogene"},{"issue":"6255","key":"2859_CR34","doi-asserted-by":"publisher","first-page":"aaa5612","DOI":"10.1126\/science.aaa5612","volume":"349","author":"C Kang","year":"2015","unstructured":"Kang C, Xu Q, Martin TD, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science, 2015,349(6255):aaa5612","journal-title":"Science"},{"issue":"12","key":"2859_CR35","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1111\/iej.13180","volume":"52","author":"W Qiao","year":"2019","unstructured":"Qiao W, Huang Y, Bian Z, et al. Lipopolysaccharide-induced DNA damage response activates nuclear factor \u03baB signalling pathway via GATA4 in dental pulp cells. Int Endod J, 2019,52(12):1704\u20131715","journal-title":"Int Endod J"},{"issue":"1","key":"2859_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.molcel.2010.09.008","volume":"40","author":"M Hinz","year":"2010","unstructured":"Hinz M, Stilmann M, Arslan S \u00c7, et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-\u03baB activation. Mol Cell, 2010,40(1):63\u201374","journal-title":"Mol Cell"},{"issue":"13","key":"2859_CR37","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1093\/nar\/gku529","volume":"42","author":"L Fang","year":"2014","unstructured":"Fang L, Choudhary S, Zhao Y, et al. ATM regulates NF-\u03baB-dependent immediate-early genes via RelA Ser 276 phosphorylation coupled to CDK9 promoter recruitment. Nucleic Acids Res, 2014,42(13):8416\u20138432","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2859_CR38","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.7150\/thno.50905","volume":"11","author":"M Zhao","year":"2021","unstructured":"Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics, 2021,11(4):1845\u20131863","journal-title":"Theranostics"},{"issue":"6632","key":"2859_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/387520a0","volume":"387","author":"T Shafman","year":"1997","unstructured":"Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature, 1997,387(6632):520\u2013523","journal-title":"Nature"},{"issue":"4","key":"2859_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41418-021-00886-w","volume":"29","author":"X Liu","year":"2022","unstructured":"Liu X, Rong F, Tang J, et al. Repression of p53 function by SIRT5-mediated desuccinylation at Lysine 120 in response to DNA damage. Cell Death Differ, 2022,29(4):722\u2013736","journal-title":"Cell Death Differ"},{"key":"2859_CR41","doi-asserted-by":"publisher","first-page":"661323","DOI":"10.3389\/fimmu.2021.661323","volume":"12","author":"IW Tengesdal","year":"2021","unstructured":"Tengesdal IW, Dinarello A, Powers NE, et al. Tumor NLRP3-Derived IL-1\u03b2 Drives the IL-6\/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. Front Immunol, 2021,12:661323","journal-title":"Front Immunol"},{"issue":"4","key":"2859_CR42","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","volume":"50","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity, 2019,50(4):778\u2013795","journal-title":"Immunity"},{"key":"2859_CR43","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3389\/fimmu.2019.01426","volume":"10","author":"E Fahey","year":"2019","unstructured":"Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis. Front Immunol, 2019,10:1426","journal-title":"Front Immunol"},{"issue":"2","key":"2859_CR44","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1002\/mco2.242","volume":"4","author":"C Xu","year":"2023","unstructured":"Xu C, Xia Y, Zhang BW, et al. Macrophages facilitate tumor cell PD-L1 expression via an IL-1\u03b2-centered loop to attenuate immune checkpoint blockade. MedComm (2020), 2023,4(2):e242","journal-title":"MedComm (2020)"},{"issue":"5","key":"2859_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020,38(5):685\u2013700","journal-title":"Cancer Cell"},{"issue":"6","key":"2859_CR46","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.ymthe.2021.04.029","volume":"29","author":"Y Xu","year":"2021","unstructured":"Xu Y, Song G, Xie S, et al. The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther, 2021,29(6):1958\u20131969","journal-title":"Mol Ther"},{"key":"2859_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-540-37696-5_5","volume":"174","author":"S Rose John","year":"2007","unstructured":"Rose John S, Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res, 2007,174:57\u201366","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"2859_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell, 1999,98(3):295\u2013303","journal-title":"Cell"},{"issue":"4","key":"2859_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018,15(4):234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"issue":"39","key":"2859_CR50","doi-asserted-by":"publisher","first-page":"36167","DOI":"10.1074\/jbc.M203184200","volume":"277","author":"T Matsui","year":"2002","unstructured":"Matsui T, Kinoshita T, Hirano T, et al. STAT3 down-regulates the expression of cyclin D during liver development. J Biol Chem, 2002,277(39):36167\u201336173","journal-title":"J Biol Chem"},{"issue":"5","key":"2859_CR51","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0960327115595686","volume":"35","author":"AS Yar Saglam","year":"2016","unstructured":"Yar Saglam AS, Alp E, Elmazoglu Z, et al. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK\/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol, 2016,35(5):526\u2013543","journal-title":"Hum Exp Toxicol"},{"issue":"12","key":"2859_CR52","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018,18(12):773\u2013789","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2859_CR53","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014,6(10):a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"2859_CR54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2016.04.036","volume":"377","author":"D Li","year":"2016","unstructured":"Li D, Xie K, Zhang L, et al. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects. Cancer Lett, 2016,377(2):164\u2013173","journal-title":"Cancer Lett"},{"issue":"5","key":"2859_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","volume":"8","author":"C Dong","year":"2008","unstructured":"Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol, 2008,8(5):337\u2013348","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2859_CR56","doi-asserted-by":"publisher","first-page":"e000949","DOI":"10.1136\/jitc-2020-000949","volume":"8","author":"R Weber","year":"2020","unstructured":"Weber R, Riester Z, H\u00fcser L, et al. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. J Immunother Cancer, 2020,8(2):e000949","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2859_CR57","doi-asserted-by":"publisher","first-page":"e002856","DOI":"10.1136\/jitc-2021-002856","volume":"9","author":"K Magidey-Klein","year":"2021","unstructured":"Magidey-Klein K, Cooper TJ, Kveler K, et al. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. J Immunother Cancer, 2021,9(6):e002856","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2859_CR58","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41375-020-01085-1","volume":"35","author":"Z iang","year":"2021","unstructured":"iang Z, Liao R, Lv J, et al. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia, 2021,35(5):1380\u20131391","journal-title":"Leukemia"},{"issue":"7355","key":"2859_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 2011,475(7355):222\u2013225","journal-title":"Nature"},{"key":"2859_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fonc.2019.00231","volume":"9","author":"Z Yang","year":"2019","unstructured":"Yang Z, Li H, Wang W, et al. CCL2\/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages. Front Oncol, 2019,9:231","journal-title":"Front Oncol"},{"issue":"1","key":"2859_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","volume":"19","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer, 2020,19(1):41","journal-title":"Mol Cancer"},{"issue":"2","key":"2859_CR62","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro JA, Luo D, Gopinath A, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci U S A, 2020,117(2):1129\u20131138","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2859_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nrc1473","volume":"4","author":"RJ Epstein","year":"2004","unstructured":"Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004,4(11):901\u2013909","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2859_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","volume":"21","author":"I Heidegger","year":"2022","unstructured":"Heidegger I, Fotakis G, Offermann A, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer, 2022,21(1):132","journal-title":"Mol Cancer"},{"issue":"1","key":"2859_CR65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7150\/thno.4922","volume":"3","author":"O Wald","year":"2013","unstructured":"Wald O, Shapira OM, Izhar U. CXCR4\/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics, 2013,3(1):26\u201333","journal-title":"Theranostics"},{"key":"2859_CR66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopha.2015.01.020","volume":"71","author":"ZY Song","year":"2015","unstructured":"Song ZY, Gao ZH, Chu JH, et al. Downregulation of the CXCR4\/CXCL12 axis blocks the activation of the Wnt\/\u03b2-catenin pathway in human colon cancer cells. Biomed Pharmacother, 2015,71:46\u201352","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2859_CR67","doi-asserted-by":"publisher","first-page":"9724","DOI":"10.1002\/jcb.28253","volume":"120","author":"X Yin","year":"2019","unstructured":"Yin X, Liu Z, Zhu P, et al. CXCL12\/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K\/AKT signal pathway. J Cell Biochem, 2019,120(6):9724\u20139736","journal-title":"J Cell Biochem"},{"issue":"17","key":"2859_CR68","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou W, Guo S, Liu M, et al. Targeting CXCL12\/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem, 2019,26(17):3026\u20133041","journal-title":"Curr Med Chem"},{"issue":"3","key":"2859_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10456-016-9509-6","volume":"19","author":"ME Ziegler","year":"2016","unstructured":"Ziegler ME, Hatch MMS, Wu N, et al. mTORC2 mediates CXCL12-induced angiogenesis. Angiogenesis, 2016,19(3):359\u2013371","journal-title":"Angiogenesis"},{"issue":"3","key":"2859_CR70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.bbrc.2007.05.182","volume":"359","author":"Z Liang","year":"2007","unstructured":"Liang Z, Brooks J, Willard M, et al. CXCR4\/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun, 2007,359(3):716\u2013722","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2859_CR71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41416-019-0497-3","volume":"121","author":"M Lecavalier-Barsoum","year":"2019","unstructured":"Lecavalier-Barsoum M, Chaudary N, Han K, et al. Targeting CXCL12\/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy. Br J Cancer, 2019,121(3):249\u2013256","journal-title":"Br J Cancer"},{"key":"2859_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1476-4598-5-56","volume":"5","author":"J Pan","year":"2006","unstructured":"Pan J, Mestas J, Burdick MD, et al. Stromal derived factor-1 (SDF-1\/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer, 2006,5:56","journal-title":"Mol Cancer"},{"issue":"1","key":"2859_CR73","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"M Taki","year":"2018","unstructured":"Taki M, Abiko K, Baba T, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun, 2018,9(1):1685","journal-title":"Nat Commun"},{"issue":"3","key":"2859_CR74","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2018.05.051","volume":"155","author":"B Garg","year":"2018","unstructured":"Garg B, Giri B, Modi S, et al. NF\u03baB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. Gastroenterology, 2018,155(3):880\u2013891","journal-title":"Gastroenterology"},{"issue":"13","key":"2859_CR75","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1182\/blood-2007-04-084210","volume":"110","author":"H Kohara","year":"2007","unstructured":"Kohara H, Omatsu Y, Sugiyama T, et al. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood, 2007,110(13):4153\u20134160","journal-title":"Blood"},{"issue":"6","key":"2859_CR76","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar2336","volume":"9","author":"C de Rham","year":"2007","unstructured":"de Rham C, Ferrari-Lacraz S, Jendly S, et al. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther, 2007,9(6):R125","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2859_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 2003,3(2):133\u2013146","journal-title":"Nat Rev Immunol"},{"key":"2859_CR78","doi-asserted-by":"publisher","first-page":"568630","DOI":"10.3389\/fimmu.2020.568630","volume":"11","author":"PS Renavikar","year":"2020","unstructured":"Renavikar PS, Sinha S, Brate AA, et al. IL-12-Induced Immune Suppressive Deficit During CD8+ T-Cell Differentiation. Front Immunol, 2020,11:568630","journal-title":"Front Immunol"},{"issue":"2","key":"2859_CR79","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/rheumatology\/kex186","volume":"57","author":"A Schurich","year":"2018","unstructured":"Schurich A, Raine C, Morris V, et al. The role of IL-12\/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford), 2018,57(2):246\u2013254","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2859_CR80","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12. Immunity, 2018,49(6):1148\u20131161","journal-title":"Immunity"},{"key":"2859_CR81","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-7-5","volume":"7","author":"A Albini","year":"2009","unstructured":"Albini A, Brigati C, Ventura A, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med, 2009,7:5","journal-title":"J Transl Med"},{"issue":"11","key":"2859_CR82","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2217\/imt-2019-0217","volume":"12","author":"MH Abdolvahab","year":"2020","unstructured":"Abdolvahab MH, Darvishi B, Zarei M, et al. Interferons: role in cancer therapy. Immunotherapy, 2020,12(11):833\u2013855","journal-title":"Immunotherapy"},{"issue":"9","key":"2859_CR83","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella M, Guarracino A, Manduca N, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol, 2022,23(9):1379\u20131392","journal-title":"Nat Immunol"},{"key":"2859_CR84","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2017.00304","volume":"8","author":"L M\u00fcller","year":"2017","unstructured":"M\u00fcller L, Aigner P, Stoiber D. Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol, 2017,8:304","journal-title":"Front Immunol"},{"issue":"11","key":"2859_CR85","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/gt.2013.31","volume":"20","author":"W Jiang","year":"2013","unstructured":"Jiang W, Zhang C, Tian Z, et al. hIFN-\u03b1 gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther, 2013,20(11):1062\u20131069","journal-title":"Gene Ther"},{"issue":"9","key":"2859_CR86","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res, 2011,17(9):2619\u20132627","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2859_CR87","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/eji.201445036","volume":"45","author":"SA Olalekan","year":"2015","unstructured":"Olalekan SA, Cao Y, Hamel KM, et al. B cells expressing IFN-\u03b3 suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol, 2015,45(4):988\u2013998","journal-title":"Eur J Immunol"},{"issue":"20","key":"2859_CR88","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","volume":"72","author":"V Sisirak","year":"2012","unstructured":"Sisirak V, Faget J, Gobert M, et al. Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res, 2012,72(20):5188\u20135197","journal-title":"Cancer Res"},{"issue":"10","key":"2859_CR89","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1172\/JCI127458","volume":"129","author":"J Chen","year":"2019","unstructured":"Chen J, Cao Y, Markelc B, et al. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J Clin Invest, 2019,129(10):4224\u20134238","journal-title":"J Clin Invest"},{"issue":"22","key":"2859_CR90","doi-asserted-by":"publisher","first-page":"e120638","DOI":"10.1172\/jci.insight.120638","volume":"3","author":"N Cheng","year":"2018","unstructured":"Cheng N, Watkins-Schulz R, Junkins RD, et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight, 2018,3(22):e120638","journal-title":"JCI Insight"},{"issue":"13","key":"2859_CR91","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/glia.20544","volume":"55","author":"MC Yadav","year":"2007","unstructured":"Yadav MC, Burudi EME, Alirezaei M, et al. IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia, 2007,55(13):1385\u20131396","journal-title":"Glia"},{"key":"2859_CR92","doi-asserted-by":"publisher","first-page":"1074440","DOI":"10.3389\/fimmu.2022.1074440","volume":"13","author":"F Pinci","year":"2022","unstructured":"Pinci F, Gaidt MM, Jung C, et al. Tumor necrosis factor is a necroptosis-associated alarmin. Front Immunol, 2022,13:1074440","journal-title":"Front Immunol"},{"issue":"12","key":"2859_CR93","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/bjc.1996.652","volume":"74","author":"PT Nooijen","year":"1996","unstructured":"Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer, 1996,74(12):1908\u20131915","journal-title":"Br J Cancer"},{"issue":"4","key":"2859_CR94","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1054\/bjoc.1999.1027","volume":"82","author":"AH van der Veen","year":"2000","unstructured":"van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer, 2000,82(4):973\u2013980","journal-title":"Br J Cancer"},{"issue":"18","key":"2859_CR95","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1073\/pnas.84.18.6563","volume":"84","author":"D Spriggs","year":"1987","unstructured":"Spriggs D, Imamura K, Rodriguez C, et al. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A, 1987,84(18):6563\u20136566","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2B","key":"2859_CR96","first-page":"1355","volume":"21","author":"AJ Karayiannakis","year":"2001","unstructured":"Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res, 2001,21(2B):1355\u20131358","journal-title":"Anticancer Res"},{"issue":"7","key":"2859_CR97","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/10552","volume":"5","author":"RJ Moore","year":"1999","unstructured":"Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 1999,5(7):828\u2013831","journal-title":"Nat Med"},{"issue":"10","key":"2859_CR98","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0277-5379(90)90043-S","volume":"26","author":"MS Naylor","year":"1990","unstructured":"Naylor MS, Malik ST, Stamp GW, et al. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer, 1990,26(10):1027\u20131030","journal-title":"Eur J Cancer"},{"issue":"1","key":"2859_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu D, Baldasici O, Balacescu O, et al. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr), 2020,43(1):1\u201318","journal-title":"Cell Oncol (Dordr)"},{"key":"2859_CR100","doi-asserted-by":"publisher","first-page":"155214","DOI":"10.1016\/j.cyto.2020.155214","volume":"135","author":"SK Schr\u00f6der","year":"2020","unstructured":"Schr\u00f6der SK, Asimakopoulou A, Tillmann S, et al. TNF-\u03b1 controls Lipocalin-2 expression in PC-3 prostate cancer cells. Cytokine, 2020,135:155214","journal-title":"Cytokine"},{"issue":"1","key":"2859_CR101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4143\/crt.2019.145","volume":"52","author":"GP Zhang","year":"2020","unstructured":"Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-\u03b1\/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat, 2020,52(1):10\u201323","journal-title":"Cancer Res Treat"},{"issue":"12","key":"2859_CR102","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.21037\/apm-21-3471","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-\u03b1 (TNF-\u03b1) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med, 2021,10(12):12759\u201312766","journal-title":"Ann Palliat Med"},{"issue":"1","key":"2859_CR103","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1006\/clin.1995.1054","volume":"75","author":"S Edamitsu","year":"1995","unstructured":"Edamitsu S, Matsukawa A, Ohkawara S, et al. Role of TNF alpha, IL-1, and IL-1ra in the mediation of leukocyte infiltration and increased vascular permeability in rabbits with LPS-induced pleurisy. Clin Immunol Immunopathol, 1995,75(1):68\u201374","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"2859_CR104","doi-asserted-by":"publisher","first-page":"13344","DOI":"10.1038\/s41598-022-17692-0","volume":"12","author":"Y Watanabe","year":"2022","unstructured":"Watanabe Y, Fukuda T, Hayashi C, et al. Extracellular vesicles derived from GMSCs stimulated with TNF-\u03b1 and IFN-\u03b1 promote M2 macrophage polarization via enhanced CD73 and CD5L expression. Sci Rep, 2022,12(1):13344","journal-title":"Sci Rep"},{"issue":"2","key":"2859_CR105","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-06-2941","volume":"67","author":"H Kulbe","year":"2007","unstructured":"Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res, 2007,67(2):585\u2013592","journal-title":"Cancer Res"},{"issue":"4","key":"2859_CR106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/path.2120","volume":"211","author":"G J Gordon","year":"2007","unstructured":"Gordon G J, Mani M, Mukhopadhyay L, et al. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol, 2007,211(4):439\u2013446","journal-title":"J Pathol"},{"issue":"20","key":"2859_CR107","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1158\/0008-5472.CAN-07-1064","volume":"67","author":"GT Stathopoulos","year":"2007","unstructured":"Stathopoulos GT, Kollintza A, Moschos C, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res, 2007,67(20):9825\u20139834","journal-title":"Cancer Res"},{"issue":"8","key":"2859_CR108","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","volume":"20","author":"FM Lang","year":"2020","unstructured":"Lang FM, Lee KMC, Teijaro JR, et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat Rev Immunol, 2020,20(8):507\u2013514","journal-title":"Nat Rev Immunol"},{"key":"2859_CR109","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3389\/fimmu.2019.02679","volume":"10","author":"Y Zhan","year":"2019","unstructured":"Zhan Y, Lew AM, Chopin M. The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. Front Immunol, 2019,10:2679","journal-title":"Front Immunol"},{"key":"2859_CR110","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol, 2018,9:113","journal-title":"Front Physiol"},{"issue":"2","key":"2859_CR111","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1702503","volume":"26","author":"H Celebi","year":"2000","unstructured":"Celebi H, Akan H, Ak\u00e7a\u011flayan E, et al. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant, 2000,26(2):211\u2013214","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2859_CR112","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/sj.bmt.1704467","volume":"33","author":"B Lemieux","year":"2004","unstructured":"Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant, 2004,33(9):921\u2013923","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"2859_CR113","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/bloodadvances.2017006858","volume":"1","author":"E Ribechini","year":"2017","unstructured":"Ribechini E, Hutchinson JA, Hergovits S, et al. Novel GM-CSF signals via IFN-\u03b3R\/IRF-1 and AKT\/mTOR license monocytes for suppressor function. Blood Adv, 2017,1(14):947\u2013960","journal-title":"Blood Adv"},{"issue":"1","key":"2859_CR114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-009-0622-8","volume":"123","author":"JK Morales","year":"2010","unstructured":"Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat, 2010,123(1):39\u201349","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2859_CR115","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/1878-0261.13450","volume":"17","author":"V Comunanza","year":"2023","unstructured":"Comunanza V, Gigliotti C, Lamba S, et al. Dual VEGFA\/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages. Mol Oncol, 2023,17(8):1474\u20131491","journal-title":"Mol Oncol"},{"issue":"1","key":"2859_CR116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/0008-5472.CAN-15-0869","volume":"76","author":"E Van Overmeire","year":"2016","unstructured":"Van Overmeire E, Stijlemans B, Heymann F, et al. M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer Res, 2016,76(1):35\u201342","journal-title":"Cancer Res"},{"issue":"1","key":"2859_CR117","first-page":"129","volume":"20","author":"JL Owen","year":"2007","unstructured":"Owen JL, Torroella-Kouri M, Handel-Fernandez ME, et al. GM-CSF up-regulates the expression of CCL2 by T lymphocytes in mammary tumor-bearing mice. Int J Mol Med, 2007,20(1):129\u2013136","journal-title":"Int J Mol Med"},{"issue":"8","key":"2859_CR118","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.4049\/jimmunol.1302821","volume":"192","author":"E Sierra-Filardi","year":"2014","unstructured":"Sierra-Filardi E, Nieto C, Dom\u00ednguez-Soto A, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2\/CCR2-dependent gene expression profile. J Immunol, 2014,192(8):3858\u20133867","journal-title":"J Immunol"},{"issue":"2","key":"2859_CR119","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1189\/jlb.0310154","volume":"89","author":"P Bhattacharya","year":"2011","unstructured":"Bhattacharya P, Gopisetty A, Ganesh BB, et al. GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol, 2011,89(2):235\u2013249","journal-title":"J Leukoc Biol"},{"issue":"12","key":"2859_CR120","doi-asserted-by":"publisher","first-page":"e20190706","DOI":"10.1084\/jem.20190706","volume":"217","author":"IC Arnold","year":"2020","unstructured":"Arnold IC, Artola-Boran M, Gurtner A, et al. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J Exp Med, 2020,217(12):e20190706","journal-title":"J Exp Med"},{"issue":"1","key":"2859_CR121","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol, 2012,188(1):21\u201328","journal-title":"J Immunol"},{"issue":"7676","key":"2859_CR122","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature24050","volume":"550","author":"Z Dou","year":"2017","unstructured":"Dou Z, Ghosh K, Vizioli MG, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature, 2017,550(7676):402\u2013406","journal-title":"Nature"},{"issue":"11","key":"2859_CR123","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.celrep.2016.05.023","volume":"15","author":"E Curran","year":"2016","unstructured":"Curran E, Chen X, Corrales L, et al. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep, 2016,15(11):2357\u20132366","journal-title":"Cell Rep"},{"issue":"5","key":"2859_CR124","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity, 2014,41(5):830\u2013842","journal-title":"Immunity"},{"issue":"2","key":"2859_CR125","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","volume":"26","author":"TF Gajewski","year":"2015","unstructured":"Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev, 2015,26(2):175\u2013178","journal-title":"Cytokine Growth Factor Rev"},{"issue":"41","key":"2859_CR126","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1038\/onc.2014.457","volume":"34","author":"J Ahn","year":"2015","unstructured":"Ahn J, Konno H, Barber GN. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene, 2015,34(41):5302\u20135308","journal-title":"Oncogene"},{"issue":"2","key":"2859_CR127","doi-asserted-by":"publisher","first-page":"e20200844","DOI":"10.1084\/jem.20200844","volume":"218","author":"N Xu","year":"2021","unstructured":"Xu N, Palmer DC, Robeson AC, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med, 2021,218(2):e20200844","journal-title":"J Exp Med"},{"issue":"7604","key":"2859_CR128","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature18268","volume":"533","author":"Q Chen","year":"2016","unstructured":"Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature, 2016,533(7604):493\u2013498","journal-title":"Nature"},{"issue":"8","key":"2859_CR129","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","volume":"76","author":"H Lemos","year":"2016","unstructured":"Lemos H, Mohamed E, Huang L, et al. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res, 2016,76(8):2076\u20132081","journal-title":"Cancer Res"},{"issue":"11","key":"2859_CR130","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.bbadis.2015.08.011","volume":"1852","author":"L Ding","year":"2015","unstructured":"Ding L, Huang XF, Dong GJ, et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun\/CCL22 signal. Biochim Biophys Acta, 2015,1852(11):2494\u20132503","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2859_CR131","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41467-020-20664-5","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar S, Nandi A, Singh S, et al. Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-\u03baB survival pathway. Nat Commun, 2021,12(1):432","journal-title":"Nat Commun"},{"issue":"7","key":"2859_CR132","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1053\/j.gastro.2022.02.035","volume":"162","author":"VK Somani","year":"2022","unstructured":"Somani VK, Zhang D, Dodhiawala PB, et al. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022,162(7):2047\u20132062","journal-title":"Gastroenterology"},{"issue":"2","key":"2859_CR133","first-page":"365","volume":"45","author":"I Gresser","year":"1970","unstructured":"Gresser I, Bourali C. Antitumor effects of interferon preparations in mice. J Natl Cancer Inst, 1970,45(2):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2859_CR134","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","volume":"4","author":"HM Golomb","year":"1986","unstructured":"Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol, 1986,4(6):900\u2013905","journal-title":"J Clin Oncol"},{"issue":"22","key":"2859_CR135","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. N Engl J Med, 1993,329(22):1608\u20131614","journal-title":"N Engl J Med"},{"issue":"7","key":"2859_CR136","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 1999,17(7):2105\u20132116","journal-title":"J Clin Oncol"},{"issue":"5","key":"2859_CR137","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7326\/0003-4819-100-5-671","volume":"100","author":"JE Groopman","year":"1984","unstructured":"Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi\u2019s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med, 1984,100(5):671\u2013676","journal-title":"Ann Intern Med"},{"issue":"6","key":"2859_CR138","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.bbi.2007.12.009","volume":"22","author":"M Majer","year":"2008","unstructured":"Majer M, Welberg LAM, Capuron L, et al. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun, 2008,22(6):870\u2013880","journal-title":"Brain Behav Immun"},{"issue":"6","key":"2859_CR139","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/hep.24306","volume":"53","author":"J Fioravanti","year":"2011","unstructured":"Fioravanti J, Gonz\u00e1lez I, Medina-Echeverz J, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology, 2011,53(6):1864\u20131873","journal-title":"Hepatology"},{"issue":"7","key":"2859_CR140","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","volume":"15","author":"U Keilholz","year":"1997","unstructured":"Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol, 1997,15(7):2579\u20132588","journal-title":"J Clin Oncol"},{"issue":"4","key":"2859_CR141","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1586\/erv.11.9","volume":"10","author":"P Rizza","year":"2011","unstructured":"Rizza P, Capone I, Moretti F, et al. IFN-\u03b1 as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev Vaccines, 2011,10(4):487\u2013498","journal-title":"Expert Rev Vaccines"},{"issue":"11\u201312","key":"2859_CR142","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00262-002-0323-1","volume":"51","author":"G Groenewegen","year":"2002","unstructured":"Groenewegen G, Bloem A, De Gast GC. PhaseI\/II study of study of sequential chemoimmunotherapy (SCIT) for metastatic metastatic melanoma: outpatient treatment with dacarbazine, dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother, 2002,51(11\u201312):630\u2013636","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2859_CR143","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","volume":"66","author":"T Di Pucchio","year":"2006","unstructured":"Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte\/dendritic cell precursors. Cancer Res, 2006,66(9):4943\u20134951","journal-title":"Cancer Res"},{"issue":"7","key":"2859_CR144","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","volume":"19","author":"ER Brown","year":"2008","unstructured":"Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol, 2008,19(7):1340\u20131346","journal-title":"Ann Oncol"},{"issue":"29","key":"2859_CR145","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","volume":"25","author":"ML Harrison","year":"2007","unstructured":"Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol, 2007,25(29):4542\u20134549","journal-title":"J Clin Oncol"},{"issue":"4","key":"2859_CR146","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res, 2021,27(4):1037\u20131047","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2859_CR147","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest, 2014,124(2):687\u2013695","journal-title":"J Clin Invest"},{"issue":"1","key":"2859_CR148","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand F, Montfort A, Marcheteau E, et al. TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun, 2017,8(1):2256","journal-title":"Nat Commun"},{"issue":"17","key":"2859_CR149","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2014.13943","volume":"312","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA, 2014,312(17):1744\u20131753","journal-title":"JAMA"},{"issue":"1","key":"2859_CR150","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-12-2","volume":"12","author":"M Martinez","year":"2012","unstructured":"Martinez M, Ono N, Planutiene M, et al. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell Int, 2012,12(1):2","journal-title":"Cancer Cell Int"},{"issue":"6","key":"2859_CR151","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel), 2021,13(6):1383","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2859_CR152","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1525-7304(11)70747-1","volume":"3","author":"K Maung","year":"2001","unstructured":"Maung K, Nemunaitis J, Cunningham C. Granulocyte macrophage colony-stimulating factor (GM-CSF) genetransduced tumor vaccines (GVAX) in non-small-cell lung cancer. Clin Lung Cancer, 2001,3(1):25\u201326","journal-title":"Clin Lung Cancer"},{"key":"2859_CR153","doi-asserted-by":"publisher","first-page":"872010","DOI":"10.3389\/fimmu.2022.872010","volume":"13","author":"SA Atallah-Yunes","year":"2022","unstructured":"Atallah-Yunes SA, Robertson MJ. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Front Immunol, 2022,13:872010","journal-title":"Front Immunol"},{"issue":"15","key":"2859_CR154","doi-asserted-by":"publisher","first-page":"e2002214","DOI":"10.1002\/adhm.202002214","volume":"10","author":"B Uricoli","year":"2021","unstructured":"Uricoli B, Birnbaum LA, Do P, et al. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater, 2021,10(15):e2002214","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"2859_CR155","first-page":"81","volume":"2","author":"CY Li","year":"2005","unstructured":"Li CY, Huang Q, Kung HF. Cytokine and immunogene therapy for solid tumors. Cell Mol Immunol, 2005,2(2):81\u201391","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2859_CR156","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1008304721889","volume":"10","author":"P Nanni","year":"1999","unstructured":"Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls. Ann Oncol, 1999,10(3):261\u2013266","journal-title":"Ann Oncol"},{"issue":"1","key":"2859_CR157","doi-asserted-by":"publisher","first-page":"e2213222120","DOI":"10.1073\/pnas.2213222120","volume":"120","author":"Y Liu","year":"2023","unstructured":"Liu Y, Adu-Berchie K, Brockman JM, et al. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A, 2023,120(1):e2213222120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2859_CR158","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0889-8588(05)70255-0","volume":"15","author":"NK Cheung","year":"2001","unstructured":"Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am, 2001,15(5):853\u2013866","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"2859_CR159","doi-asserted-by":"publisher","first-page":"eadd8564","DOI":"10.1126\/sciadv.add8564","volume":"9","author":"L Vornholz","year":"2023","unstructured":"Vornholz L, Isay SE, Kurgyis Z, et al. Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. Sci Adv, 2023,9(11):eadd8564","journal-title":"Sci Adv"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-024-2859-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-024-2859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T13:05:43Z","timestamp":1731675943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-024-2859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2859"],"URL":"https:\/\/doi.org\/10.1007\/s11596-024-2859-1","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}